Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
Conclusions:
This economic evaluation demonstrates that GXR + stimulant is cost-effective compared to stimulant alone in the treatment of children and adolescents with ADHD in Canada.
Source: Epidemiologic Perspectives and Innovations - Category: Epidemiology Authors: Jean LachaineVanja SikiricaKarine Mathurin Source Type: research
More News: ADHD | Amphetamine | Children | Concerta | Epidemiology | Health | Hyperactivity | Methylphenidate | Psychiatry | Ritalin | Study | Vyvanse